HMGB2 and cervical cancer: Of 29 cervical cancer samples, 9 (35.5%) samples with IRS of 0-1 were classified as low HMGB2 expression (HMGB2-low), and 20 (64.5%) samples with IRS of 2-3 were classified as high HMGB2 expression (HMGB2-high).